Clinical trials: Infections, Respiratory
Pneumonia, Pneumococcal
Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in Healthy Volunteers Aged Above 2 Months
The purpose of this study is to evaluate safety of 15-Valent Pneumococcal Conjugate Vaccine in healthy volunteers aged above 3 Months.
- Trial name
- NCT04108845
- Testing
- 15-Valent Pneumococcal Conjugate Vaccine
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Virus Diseases
Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza
Danirixin (DNX) is a novel, selective, and reversible antagonist of the C-X-C chemokine receptor (CXCR) 2 and has been shown to decrease neutrophil transmigration and activation to areas of inflammation.
- Trial name
- NCT02927431
- Testing
- Danirixin 15 mg FBE, Danirixin 50 mg FBE, Oseltamivir 75 mg
- Where
- 8 sites in United States, Romania and 2 more
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Covid19
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19.
- Trial name
- NCT04913675
- Testing
- sotrovimab
- Where
- 50 sites in United States, France and 1 more
- Volunteers
- 1,065 people
- Sponsor
- Vir Biotechnology, Inc.
COVID, ARDS, Human
Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)
This protocol proposes to use IC14, a recombinant chimeric monoclonal antibody (mAb) recognizing human CD14, to block CD14-mediated cellular activation in patients early in the development of ARDS.
- Conditions
- COVID, ARDS, Human, Ards, SARS-CoV2
- Trial name
- NCT04346277
- Testing
- IC14, a monoclonal antibody against CD14
- Where
- Italy
- Sponsor
- Implicit Bioscience
Covid19
COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines
This is a phase 1/2 study in adult healthy subjects that have previously been vaccinated with an FDA-authorized vaccine against COVID-19.
- Trial name
- NCT04843722
- Testing
- hAd5-S-Fusion+N-ETSD vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Respiratory Syncytial Virus (RSV)
A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus
This is a Phase 3b, prospective, multicenter, open-label, non-controlled study to assess the safety and effectiveness of immunoprophylaxis with the intramuscular (IM) administration of the liquid formulation of palivizumab for…
- Trial name
- Synagis Russia (NCT02968173)
- Testing
- Palivizumab
- Volunteers
- 50 people
- Sponsor
- AbbVie
Influenza, Human
Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years
To evaluate the safety and immunogenicity of quadrivalent influenza virus split vaccine in healthy population aged 3-8 years following different immunization procedures.
- Trial name
- NCT05138705
- Testing
- Quadrivalent Influenza Virus Split Vaccine
- Where
- China
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
COVID-19 SARS-CoV-2 Infection, COVID-19
A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19
The purpose of this study is to learn about how well the yearly updates to the COVID-19 vaccine work in adults (age 18 years and above) with a healthy immune system (the body's cells, tissues and organs that work together to…
- Conditions
- COVID-19 SARS-CoV-2 Infection, COVID-19, COVID-19 Infection, Coronavirus Disease 2019 (COVID-19)
- Trial name
- NCT06923137
- Testing
- BNT162b2
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Influenza
Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)
Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously vaccinated in Trial V118_05.
- Trial name
- NCT02583256
- Testing
- Adjuvanted QIV (aQIV), Non-adjuvanted QIV
- Where
- 17 sites in Finland, Philippines and 1 more
- Volunteers
- 1,601 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers
The purpose of this study is to determine the efficacy of the liquid formulation of CAIVT against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months, attending day care centers…
- Trial name
- NCT00192283
- Testing
- CAIV-T
- Where
- Finland
- Volunteers
- 2,903 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
COVID-19
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
This is a phase 2/3, multicenter, randomized, placebo-controlled, observer-blind study assessing the safety, tolerability, immunogenicity, and efficacy of prophylactic hAd5-S-Fusion+N-ETSD against COVID-19.
- Trial name
- NCT06022224
- Testing
- hAd5-S-Fusion+N-ETSD
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
SARS-CoV-2 Infection
Halodine Nasal Antiseptic in Patients With COVID-19
Povidone iodine (PVP-I) is a well-known broad spectrum, resistance free antimicrobial agent that has a long history of safe and effective use.
- Trial name
- NCT04517188
- Testing
- Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP
- Volunteers
- 40 people
- Sponsor
- Halodine LLC
Pneumonia, Bacterial, Healthy Volunteers
A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of 3 different dose levels of ASP3772 in comparison to the active comparator Prevnar 13® (PCV13) in adults 18 to 64 years of age in Stage 1.
- Conditions
- Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease
- Trial name
- NCT03803202
- Testing
- ASP3772, PCV13, PPSV23
- Where
- 26 sites in United States
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea.
The purpose of this study is to collect safety information on the use of Fluarix Tetra according to the approved PI, in Korea, over a period of 6 years from children greater than or equal to (≥)3 years of age and adults, and over…
- Trial name
- NCT02663102
- Testing
- Data collection
- Where
- 21 sites in South Korea
- Volunteers
- 1,388 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza
This is safety and pharmacokinetics (PK) of favipiravir study in adults 18-80 years of age diagnosed with uncomplicated influenza.
- Trial name
- FAVOR (NCT01728753)
- Testing
- Favipiravir
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- MDVI, LLC
COVID-19
A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to evaluate the efficacy, immunogenicity, reactogenicity and safety of an adjuvanted recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)…
- Trial name
- SCB-2019 (NCT04672395)
- Testing
- CpG 1018/Alum-adjuvanted SCB-2019 vaccine, SCB-2019 vaccine
- Where
- 31 sites in Belgium, Brazil and 3 more
- Volunteers
- 31,454 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
COVID-19
Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong
This is a randomized, double-blinded, Phase IIb clinical trial of COVID-19 vaccine (CoronaVac®) manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate to evaluate the changes in…
- Trial name
- NCT05254236
- Testing
- COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose), COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
SARS-CoV-2, Covid19
Clinical Evaluation of a Point-of-Care (POC), COVID-19 Rapid Antigen Test (CoviDx™)
Prospective study that will evaluate the clinical agreement of the CoviDx™ Rapid Antigen test compared to SARS-CoV-2 RT-PCR.
- Trial name
- CoviDx (NCT04750629)
- Testing
- POC CoviDx™ Rapid Antigen Test
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Lumos Diagnostics
Influenza A, Influenza B, Influenza Vaccination
Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older
This is a multicenter, randomized, double-blind, active-controlled, parallel-group clinical trial in adults aged 65 years or older.
- Trial name
- GC3114B (NCT07883928)
- Testing
- vaccination of GC3114B, Vaccination of Efluelda
- Where
- South Korea
- Volunteers
- 1,806 people, healthy volunteers welcome
- Sponsor
- GC Biopharma Corp
COVID-19, Coronavirus
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects with mild to moderate COVID-19 who test…
- Conditions
- COVID-19, Coronavirus, SARS-CoV2 Infection
- Trial name
- NCT04551911
- Testing
- Rayaldee
- Where
- 10 sites in United States
- Volunteers
- 171 people
- Sponsor
- OPKO Health, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.